Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879680 | 1.00 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2MAPTF7 | |
| SCHEMBL9527552 | 1.00 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2MAPTF7 | |
| SCHEMBL11874320 | 0.96 | KEAP1 (0.46) | HCAR2KEAP1NFE2L2MAPTF7 | |
| SCHEMBL11874324 | 0.96 | KEAP1 (0.46) | HCAR2KEAP1NFE2L2MAPTF7 | |
| SCHEMBL1404268 | 0.94 | CNR1 (0.49) | HCAR2KEAP1NFE2L2MAPTF7 | |
| SCHEMBL1404267 | 0.94 | CNR1 (0.49) | HCAR2KEAP1NFE2L2MAPTF7 | |
| SCHEMBL11743976 | 0.92 | PPARG (0.51) | MAPTF7F3ATMCNR1 | |
| SCHEMBL347470 | 0.92 | PPARG (0.51) | MAPTF7F3ATMCNR1 | |
| SCHEMBL22555434 | 0.92 | PPARG (0.51) | MAPTF7F3ATMCNR1 | |
| SCHEMBL14672999 | 0.92 | PPARG (0.51) | MAPTF7F3ATMCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003467-A | Novel triphosphine compound and synthetic method and application thereof | 惠州凯特立斯科技有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-115772195-A | Pyridine-based phosphine ligand compound and application thereof | 惠州凯特立斯科技有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-114957327-A | Synthesis method of benzene-based tetraphosphine ligand | 惠州凯特立斯科技有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114835746-A | Novel tetradentate phosphine ligand compound and synthetic method and application thereof | 惠州凯特立斯科技有限公司 | 2022-08-02 | — | — | CN | claimed |
| CN-114805434-A | Novel tetradentate phosphine ligand compound and synthetic method and application thereof | 惠州凯特立斯科技有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-12-18 | — | — | US | claimed |
| US-20080247966-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-10-09 | — | — | US | claimed |
| EP-1937365-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-07-02 | — | — | EP | claimed |
| EP-1919566-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007025401-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| WO-2007025402-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| JP-1305051-A | — | — | None | — | — | JP | disclosed |
| CN-116640072-B | Method for synthesizing oxime compound by catalyzing hydrocarbon bond oxidation through tetradentate nitrogen-containing coordination manganese | 陕西师范大学 | 2025-02-28 | — | — | CN | disclosed |
| WO-2023178197-A1 | RECOMBINANT MICROBES FOR PRODUCTION OF TRANS-2 UNSATURATED FATTY ACIDS AND DERIVATIVES THEREOF | GENOMATICA, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-116640072-A | Method for synthesizing oxime compound by catalyzing hydrocarbon bond oxidation through tetradentate nitrogen-containing coordination manganese | 陕西师范大学 | 2023-08-25 | — | — | CN | disclosed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| JP-H01305051-A | PRODUCTION OF OMEGA ENECARBOXYLIC ESTER | HUELS AG | 1989-12-08 | — | — | JP | disclosed |
| EP-0334455-A1 | Process for the production of keto-diesters | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-09-27 | — | — | EP | disclosed |
| US-4800231-A | Keto-diesters production | SHELL OIL COMPANY (US) | 1989-01-24 | — | — | US | disclosed |
| US-4052423-A | FROM A VINYLMERCURIC HALIDE, CARBON MONOXIDE AND ALCOHOL | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | TAS2R60, TAS2R40, LPO | HCAR2 1404/4885KEAP1 406/4885NFE2L2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.